Health ❯Medical Research ❯Clinical Trials ❯Animal Studies
New preclinical data presented at ECO25 reveals tirzepatide’s transient energy expenditure boost and semaglutide’s initial metabolic slowdown, with both drugs’ effects reversing after treatment ends.